scispace - formally typeset
J

John R. Crison

Researcher at Bristol-Myers Squibb

Publications -  39
Citations -  7157

John R. Crison is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Dissolution testing & Solubility. The author has an hindex of 21, co-authored 39 publications receiving 6608 citations. Previous affiliations of John R. Crison include Pfizer & Simulations Plus, Inc..

Papers
More filters
Journal ArticleDOI

A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability

TL;DR: A biopharmaceutics drug classification scheme for correlating in vitro drug product dissolution and in vivo bioavailability is proposed based on recognizing that drug dissolution and gastrointestinal permeability are the fundamental parameters controlling rate and extent of drug absorption.
Journal ArticleDOI

Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption.

TL;DR: This review focuses on the dynamic models, which predict both the fraction of dose absorbed and the rate of drug absorption and can be related to pharmacokinetic models to evaluate plasma concentration profiles.
Journal ArticleDOI

Compartmental transit and dispersion model analysis of small intestinal transit flow in humans

TL;DR: It was demonstrated that the small intestinal transit flow profile was well characterized by both compartmental transit and dispersion models, but not by the single-compartment model, and it was concluded that the compartmental Transit model might be superior to thesingle-compartments model and less complex than the dispersion model.
Journal ArticleDOI

Dissolution of ionizable water-insoluble drugs: the combined effect of pH and surfactant.

TL;DR: This model may be useful in predicting the dissolution of an ionizable water insoluble drug as a function of pH and surfactant and for establishing in vitro-in vivo correlations, IVIVC, for maintaining bioequivalence of drug products.